spacer
home > ict > autumn 2009 > cutting back
PUBLICATIONS
International Clinical Trials

Cutting Back

 

The golden age of the pharmaceutical industry in which pipelines were full and cash cows were ample seems to be fading away. Pipelines are getting thinner and patent time is quickly running out on existing revenue-generating products. To keep the pharmaceutical industry viable, innovative solutions are needed to cut back on the time and costs of clinical development.

The first cuts began about 15 years ago, when the industry realised that the consecutive phases of clinical development could be run in parallel. Twenty years ago, Phase I studies were generally run before Phase II studies, which in turn were completed before Phase III studies. Now, outside of the initial first-in-man and perhaps a Phase IIa dose-finding study, most Phase I studies are run alongside the Phase II and Phase III programme. But that was only the beginning. The pressure to compress clinical development time continues to grow, and managers are trying to find ways to shorten the time to get their products to market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After receiving her PhD in developmental neurobiology, Julia Forjanic Klapproth started her career as a Medical Writer in the pharmaceutical industry at Hoechst Marion Roussel (later Aventis) in 1997. Since then she has been President of the European Medical Writers Association (EMWA) twice (2001-2002, 2007-2009). Julia is also an experienced trainer of medical writers, regularly running workshops for EMWA and pharmaceutical companies around the world. In 2002, Julia co-founded Trilogy Writing & Consulting, a company specialised in providing medical writing. In addition to company management activities as Senior Partner and CEO, she continues to contribute her enthusiasm to client projects, writing a wide array of clinical documents. Numerous clients have depended on and appreciated her expertise in writing and coordinating study protocols, study reports, and CTD submission dossiers.
spacer
Julia Forjanic Klapproth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: itís where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on todayís hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement